Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
Date:10/21/2008

SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today announced that a single institutional investor shall purchase, for $24.7 million, newly issued 9.66% Convertible Senior Notes due 2011, with a conversion price of $0.38 per share.

The new Notes would have a $24.7 million initial principal balance and feature a make-whole provision entitling the holder, upon any conversion of the Notes, to receive the interest payable through scheduled maturity, less any interest paid before conversion. The Company has also agreed to repurchase from the investor an aggregate amount of approximately $18.2 million of outstanding 15% Convertible Senior Notes that were issued in June 2008. For such repurchase, the Company will use $10 million of the proceeds from the offering, plus funds to be released to the Company from the escrow account that was established to pay the make-whole and interest payments on the 15% Convertible Senior Notes. Warrants to purchase approximately 1.15 million shares of common stock which were issued in connection with the approximately $18.2 million of repurchased notes are also being surrendered to the Company and will be cancelled. The Company expects to receive net proceeds of approximately $14.7 million from the new Notes (before payment of fees and expenses), after the repurchase of the June 2008 notes and prior to depositing approximately $7.2 million in escrow for the make-whole provision. The new Notes will rank equal in right of payment with all existing and future unsecured senior indebtedness of the Company.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent f
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Cell Therapeutics, Inc. Announces Reverse Stock Split
5. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
6. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
7. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
8. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
11. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Lisa Kulik saw ... this July 4 holiday, thanks to a groundbreaking retinal ... an internationally renowned clinician-researcher at the University of Southern ... 55-year-old Peoria, Ariz. resident who ... its victims of sight. On June 2, she became ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... County, Florida (PRWEB) August 27, 2014 ... Inc. (SCI) is announcing the creation of the ... is to take the SCI’s philosophy of looking ... company’s research and development actions are based on ... This new Scientific Advisory Board provides a vehicle ...
(Date:8/27/2014)... WriteResult, LLC – a premier provider ... shown superiority when it comes to meeting the needs ... portion of their most recent study closeout on-time and ... WriteResult’s digital writing platform to collect Patient Reported Outcomes ... complete drew data from a number of assessments including ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Flagship Biosciences Announces Relocation and Expansion 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2
... offers completely interactive gene-level database to explore, understand, ... May 5 GenomeQuest, Inc., the leader in ... released a Digital Gene Expression Workflow designed to ... Digital Gene Expression Workflow is the second such ...
... A new Hospital Energy Performance ... systems performance and energy efficiency by ... savings linked to low-cost modifications. The service is available ... (EH&E), a leading Massachusetts-based environmental and engineering consulting firm."Healthcare facilities ...
... DIEGO, May 5 - Evoke Pharma, Inc., a ... initiated a Phase 2b clinical trial to evaluate EVK-001 ... gastroparesis. Gastroparesis is a syndrome characterized by delayed emptying ... in the absence of mechanical obstruction. Diabetes is an ...
Cached Biology Technology:GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform 2New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3
(Date:8/27/2014)... consumers are willing to pay a premium for fruits, ... getting what the label claims is another matter. Now ... new way to make sure farms are labelling their ... Journal of Agricultural and Food Chemistry , could help ... Health and Food Safety Authority and the Wuerzburg University ...
(Date:8/27/2014)... NY (June, 2014) Outstanding basic research, a ... a dedication to patient care have earned the ... University Medical Center (CUMC) and NewYork-Presbyterian Hospital an ... the National Cancer Institute (NCI). The grant renews ... NCI-designated Comprehensive Cancer Centers in New York City ...
(Date:8/27/2014)... that health advocates, campaigns against trans-fats have largely ... they,re taking aim at sugar for its potential ... policymakers are still wrangling over the best way ... to an article in Chemical & Engineering ... the American Chemical Society. , In the article, ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4
... make,light sensitive cells in the eye by switching on ... Nature, the team from,Imperial College London and the University ... the nerve cells,causes them to become light responsive, or ... could be used to,make neurones light responsive. They found ...
... Massachusetts General Hospital (MGH) researchers discovered that the ... cells that could regenerate the insulin-producing islets of ... members of the,same team now report that these ... to be present only during the embryonic,development of ...
... Cancer Institute researchers have identified a molecular mechanism in ... consuming foods rich in saturated fats and trans-fatty acids ... increases one's risk of heart disease and certain cancers. ... led by Bruce Spiegelman, PhD, report that the harmful ...
Cached Biology News:Researchers discover way to make cells in the eye sensitive to light 2Spleen may be source of versatile stem cells 2Spleen may be source of versatile stem cells 3Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 2Scientists ID molecular 'switch' in liver that triggers harmful effects of saturated and trans fats 3
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: